IL-17A is generally considered to play a promoting role in NAFLD, while IL-17F has been reported to play a role in preventing liver function damage in NAFLD (60), which is also consistent with the results of this study. Here, IL17A is linked to metabolic dysfunction-associated steatotic liver disease.